<DOC>
	<DOCNO>NCT01859221</DOCNO>
	<brief_summary>The purpose phase II study evaluate outcomes patient treat investigational radiation regimen use stereotactic radiotherapy oligometastatic prostate cancer establish efficacy ( produce desire result effect ) safety setting .</brief_summary>
	<brief_title>Radiotherapy Oligometastatic Prostate Cancer</brief_title>
	<detailed_description>This study serve component large program investigate benefit stereotactic radiotherapy patient metastatic disease . This particular study serve benchmark analysis . All patient receive stereotactic radiotherapy direct metastatic tumor . If primary prostate cancer active previously treat radiation therapy , conventional radiation therapy ( 6-8 week daily treatment ) may recommend . The metastatic tumor treat time . Hormone therapy recommend patient . Patients ask complete questionnaire regular interval .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Patients metastatic cancer prostate , Patients may receive prior surgery , Prior radiation therapy , androgen deprivation therapy ( ADT ) , immunotherapy , bone metastasis direct therapy , chemotherapy prostate cancer . Endstage heart disease , Endstage liver disease , Endstage renal disease , End stage pulmonary disease Current brain central nervous system metastasis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Oligometastatic prostate cancer</keyword>
	<keyword>Proton radiation</keyword>
</DOC>